ROIVANT SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.03 USD | +1.38% |
|
+5.45% | -1.78% |
| Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
| Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 502.1 | 3,419 | 5,597 | 8,888 | - | - |
| Enterprise Value (EV) 1 | 502.1 | 1,568 | 5,597 | 2,586 | 3,782 | 4,464 |
| P/E ratio | -2.6 x | -3.92 x | -5.2 x | 2.12 x | -8.66 x | -8.73 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 61.8 x | 91.3 x | 13.6 x | 52 x | 26.5 x |
| EV / Revenue | - | 28.4 x | 91.3 x | 3.95 x | 22.1 x | 13.3 x |
| EV / EBITDA | - | -1.17 x | -4.84 x | -2.41 x | -3.95 x | -7.05 x |
| EV / FCF | - | - | - | 17.5 x | -3.42 x | -4.28 x |
| FCF Yield | - | - | - | 5.72% | -29.2% | -23.3% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 51,340 | 692,072 | 758,427 | 805,846 | - | - |
| Reference price 2 | 9.780 | 4.940 | 7.380 | 11.03 | 11.03 | 11.03 |
| Announcement Date | 7/1/21 | 6/28/22 | 6/28/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 55.29 | 61.28 | 654.8 | 170.8 | 336 |
| EBITDA 1 | - | -1,346 | -1,156 | -1,074 | -958.5 | -633 |
| EBIT 1 | - | -1,352 | -1,175 | 1,606 | -1,129 | -1,104 |
| Operating Margin | - | -2,444.82% | -1,917.95% | 245.19% | -660.88% | -328.67% |
| Earnings before Tax (EBT) 1 | - | -923.7 | -1,225 | 4,170 | -1,100 | -1,083 |
| Net income 1 | -809.2 | -845.3 | -1,009 | 4,253 | -997.9 | -997.2 |
| Net margin | - | -1,528.89% | -1,646.59% | 649.51% | -584.27% | -296.77% |
| EPS 2 | -3.760 | -1.260 | -1.420 | 5.212 | -1.273 | -1.264 |
| Free Cash Flow 1 | - | - | - | 148 | -1,105 | -1,042 |
| FCF margin | - | - | - | 22.6% | -646.84% | -310.18% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | 3.48% | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 7/1/21 | 6/28/22 | 6/28/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.99 | 24.34 | 9.223 | 4.319 | 12.53 | 17.05 | 27.38 | 21.62 | 37.1 | 37.14 | 31.91 | 48.8 | 35.27 | 39.12 | 44.99 |
| EBITDA 1 | - | - | - | - | -280.8 | -378.1 | -228.2 | -270.6 | -270.9 | -282.1 | -240.3 | - | - | - | - |
| EBIT 1 | -684.4 | -246 | -266.8 | -282.3 | -280.8 | -378.1 | -234.2 | -276.4 | -276.5 | 5,061 | -283.6 | -250.1 | -281.6 | -296.2 | -299.1 |
| Operating Margin | -4,893.32% | -1,010.73% | -2,892.8% | -6,536.44% | -2,240.21% | -2,217.2% | -855.37% | -1,278.27% | -745.14% | 13,626.5% | -888.85% | -512.46% | -798.6% | -757.25% | -664.93% |
| Earnings before Tax (EBT) 1 | -225.2 | -306 | -291.5 | -349.8 | -313.8 | -382.1 | -179.2 | -326.1 | -327.4 | 5,098 | -284.9 | -231 | -272.5 | -286.5 | -299.1 |
| Net income 1 | -208.5 | -284.5 | -270.1 | -331.8 | -291.6 | -352 | -33.62 | -291.8 | -304.3 | 5,096 | -255.6 | -209.7 | -246.5 | -258.6 | -270.2 |
| Net margin | -1,490.53% | -1,168.96% | -2,928.14% | -7,682.54% | -2,326.58% | -2,064.36% | -122.8% | -1,349.5% | -820.27% | 13,721.55% | -801.13% | -429.76% | -699.07% | -660.97% | -600.5% |
| EPS 2 | -0.3200 | -0.4100 | -0.3900 | -0.4800 | -0.4200 | -0.4900 | -0.0500 | -0.3800 | -0.4000 | 6.030 | -0.2987 | -0.3340 | -0.3420 | -0.3560 | -0.3580 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 2/14/22 | 6/28/22 | 8/15/22 | 11/14/22 | 2/13/23 | 6/28/23 | 8/14/23 | 11/13/23 | 2/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,850 | - | 6,302 | 5,107 | 4,424 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | 148 | -1,105 | -1,042 |
| ROE (net income / shareholders' equity) | - | -48.9% | - | 123% | -26.8% | -33.6% |
| ROA (Net income/ Total Assets) | - | - | -40.6% | 95.7% | -21.3% | -25.2% |
| Assets 1 | - | - | 2,487 | 4,445 | 4,683 | 3,957 |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | 5.660 | -1.010 | - |
| Capex 1 | - | 17.4 | - | 4.29 | 5.93 | 6.28 |
| Capex / Sales | - | 31.54% | - | 0.66% | 3.47% | 1.87% |
| Announcement Date | 7/1/21 | 6/28/22 | 6/28/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
11.03
USD
Average target price
16.08
USD
Spread / Average Target
+45.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.78% | 8.89B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ROIV Stock
- Financials Roivant Sciences Ltd.
